Vaxcyte (NASDAQ:PCVX) Stock Keeps Buy Rating at BTIG Research

Vaxcyte (NASDAQ:PCVX)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a research note issued on Monday, Marketbeat reports. They currently have a $89.00 target price on the stock. BTIG Research’s price target points to a potential upside of 36.99% from the company’s current price.

Several other analysts have also weighed in on the company. Bank of America reduced their price objective on Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research note on Monday, September 28th. Guggenheim increased their target price on Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Friday. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $108.60.

Vaxcyte Price Performance

Vaxcyte stock traded down $8.85 during mid-day trading on Monday, reaching $64.97. 5,211,490 shares of the company were exchanged, compared to its average volume of 1,477,607. The firm has a market cap of $9.67 billion, a PE ratio of -8.49 and a beta of 1.23. Vaxcyte has a 12 month low of $39.87 and a 12 month high of $90.75. The company has a fifty day simple moving average of $59.04 and a 200-day simple moving average of $56.31.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same period last year, the company posted ($1.22) earnings per share. Sell-side analysts anticipate that Vaxcyte will post -7.6 earnings per share for the current year.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total value of $538,900.00. Following the transaction, the chief financial officer owned 105,176 shares in the company, valued at approximately $5,667,934.64. This represents a 8.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harpreet Dhaliwal sold 17,000 shares of Vaxcyte stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total transaction of $935,000.00. Following the completion of the sale, the insider directly owned 76,756 shares of the company’s stock, valued at approximately $4,221,580. The trade was a 18.13% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 55,890 shares of company stock valued at $3,111,189 in the last 90 days. Corporate insiders own 3.30% of the company’s stock.

Hedge Funds Weigh In On Vaxcyte

Several large investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC boosted its stake in shares of Vaxcyte by 4.0% in the second quarter. Hsbc Holdings PLC now owns 4,151 shares of the company’s stock worth $241,000 after buying an additional 159 shares during the last quarter. Meeder Advisory Services Inc. lifted its holdings in Vaxcyte by 2.9% in the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock valued at $484,000 after acquiring an additional 231 shares during the period. IFP Advisors Inc lifted its holdings in Vaxcyte by 72.8% in the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock valued at $33,000 after acquiring an additional 236 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in Vaxcyte by 27.6% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,344 shares of the company’s stock worth $78,000 after purchasing an additional 291 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Vaxcyte by 7.0% during the 1st quarter. Principal Financial Group Inc. now owns 5,275 shares of the company’s stock worth $307,000 after purchasing an additional 343 shares during the period. Institutional investors own 96.78% of the company’s stock.

Trending Headlines about Vaxcyte

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Vaxcyte reported that its 31-valent pneumococcal vaccine candidate, VAX-31, met all prespecified primary endpoints in the OPUS-1 pivotal Phase 3 trial across the age groups studied. The results showed immune responses comparable to Pfizer’s Prevnar 20 and/or Merck’s Capvaxive, supporting VAX-31’s potential to compete in the adult pneumococcal vaccine market. Vaxcyte Reports Positive Topline Data from OPUS-1
• Positive Sentiment: Analysts responded favorably to the late-stage win. Needham raised its price target from $110 to $122 and reaffirmed a buy rating, while BTIG maintained its buy rating with an $89 target. Jefferies described the results as a potential “blue-sky” outcome and estimated the addressable adult market at roughly $3 billion to $6 billion or more. Vaxcyte Given New $122 Price Target
• Positive Sentiment: Trading volume increased substantially alongside the clinical news, and traders purchased more call options than usual on Monday, indicating heightened speculative interest in further gains.
• Neutral Sentiment: Vaxcyte is conducting additional Phase 3-related discussions and investor communications around the VAX-31 readout. The data improve the candidate’s commercial prospects, but regulatory review, manufacturing, launch execution and competitive positioning remain important risks.
• Negative Sentiment: The company launched separate offerings of approximately $500 million of common stock and pre-funded warrants and $500 million of convertible senior notes due 2032, with potential over-allotments. The financing should strengthen Vaxcyte’s balance sheet and fund development, but the equity offering creates dilution and the announcement pressured the shares after their clinical-news rally. Vaxcyte Announces Proposed Public Offerings
• Negative Sentiment: Unusually heavy put-option activity on Tuesday—8,093 contracts versus typical daily volume of 2,254—signals increased hedging or bearish speculation, although options activity alone does not establish a definitive outlook.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.